Status:
COMPLETED
DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help...
Detailed Description
OBJECTIVES: * To test the influence of killer immunoglobulin-like receptor (KIR) and human lymphocyte antigen (HLA) genotype on response to anti-CD20 antibody lymphoma immunotherapy. OUTLINE: DNA sa...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Patients diagnosed with follicular lymphoma enrolled on ECOG-E4402
- Treated with single-agent rituximab; the trial compared two different rituximab-dosing strategies - maintenance vs retreatment as needed
- Available germline DNA samples isolated from peripheral blood as well as clinical evaluation of disease status prior to and at initial response to the therapy
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
December 13 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2012
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01406782
Start Date
December 13 2011
End Date
January 13 2012
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.